Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | MAP2K1 D67N NRAS G12C PTEN del |
| Gene Variant Detail |
MAP2K1 D67N (gain of function) |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| MAP2K1 D67N NRAS G12C PTEN del | T-cell acute lymphoblastic leukemia | no benefit | Sotorasib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lumakras (sotorasib) treatment resulted in decreased Erk1/2 phosphorylation, but demonstrated only a modest effect on viability in a T-cell acute lymphoblastic leukemia cell line harboring NRAS G12C, MAP2K1 D67N, and PTEN deletion in culture, and inhibited Erk1/2 phosphorylation levels in liver-infiltrating cancer cells but did not prolong survival in a cell line xenograft model (PMID: 41340466). | 41340466 | |
| MAP2K1 D67N NRAS G12C PTEN del | T-cell acute lymphoblastic leukemia | sensitive | Copanlisib + Sotorasib | Preclinical - Cell culture | Actionable | In a preclinical study, Lumakras (sotorasib) and Aliqopa (copanlisib) synergistically inhibited viability in a T-cell acute lymphoblastic leukemia cell line harboring NRAS G12C, MAP2K1 D67N, and PTEN deletion in culture (PMID: 41340466). | 41340466 |